Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CRMD |
---|---|---|
09:32 ET | 6916 | 4.18 |
09:36 ET | 100 | 4.16 |
09:38 ET | 348 | 4.16 |
09:39 ET | 1100 | 4.15 |
09:41 ET | 1600 | 4.16 |
09:45 ET | 300 | 4.17 |
09:50 ET | 100 | 4.16 |
09:52 ET | 200 | 4.1765 |
09:54 ET | 400 | 4.16 |
09:56 ET | 200 | 4.16 |
10:01 ET | 110 | 4.16 |
10:03 ET | 5200 | 4.165 |
10:06 ET | 5210 | 4.165 |
10:08 ET | 23954 | 4.115 |
10:10 ET | 815 | 4.105 |
10:12 ET | 1200 | 4.1074 |
10:14 ET | 400 | 4.09 |
10:15 ET | 1500 | 4.09 |
10:17 ET | 800 | 4.09 |
10:19 ET | 1000 | 4.07 |
10:21 ET | 1700 | 4.08 |
10:26 ET | 210 | 4.085 |
10:28 ET | 2265 | 4.095 |
10:32 ET | 669 | 4.116 |
10:33 ET | 300 | 4.1 |
10:35 ET | 8074 | 4.1 |
10:37 ET | 1273 | 4.095 |
10:39 ET | 2000 | 4.08 |
10:42 ET | 450 | 4.08 |
10:44 ET | 200 | 4.075 |
10:46 ET | 200 | 4.075 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
CorMedix Inc | 229.8M | -4.4x | --- |
Cipla Ltd | 14.5B | 0.0x | --- |
Zevra Therapeutics Inc | 192.1M | -3.4x | --- |
Calliditas Therapeutics AB | 1.2B | -20.9x | --- |
Assembly Biosciences Inc | 94.2M | -1.4x | --- |
Incannex Healthcare Inc | 53.5M | 0.0x | --- |
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $229.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 55.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.59 |
EPS | $-0.93 |
Book Value | $1.28 |
P/E Ratio | -4.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.